In this week's episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present. Shopify's (NYSE: SHOP) strong growth in 2021 being followed by an expectation for slightly less growth in 2022. Read More...
In this week’s episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present. Shopify’s (NYSE: SHOP) strong growth in 2021 being followed by an expectation for slightly less growth in 2022.
Add Comment